Special Issue "Pneumococcal Vaccine in the 21st Century"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 31 August 2013
Dr. Stanley S. Tai
Department of Microbiology, College of Medicine, Howard University, 520 “W” Street, NW, Washington, DC 20059, USA
Phone: +1 202 806 4677
Fax: +1 202 667 9589
Interests: pneumococcal vaccine; respiratory bacterial pathogens; bacterial pathogenesis
Streptococcus pneumoniae infection is one of the leading infectious diseases with great morbidity and mortality worldwide, especially in the elderly and young children. The United States Food and Drug Administration has licensed a 7-valent pneumococcal conjugate vaccine Prevnar 7® in 2000 for use in young children. It reduces the incidence rate of invasive pneumococcal disease and acute otitis media significantly in immunized children and, via herd immunity, in adults. However, its use is limited by the variations in prevalent serotypes among different geographic areas and the increase of non-vaccine type pneumococcal infection after use. To broaden the protection, Prevnar 13® was licensed in 2010. This special issue will cover, but not limit to, the following areas: 1) the impact of Prevnar 13® on the incidence rate of pneumococcal disease in vaccinated and non-vaccinated populations, and the serotype distribution and antibiotic susceptibility of S. pneumoniae isolated from patients and healthy populations, 2) the development of new polysaccharide-based vaccines for the countries that cannot be effectively protected by Prevnar 13®, and 3) the advances in polysaccharide-independent pneumococcal vaccines, such as pneumococcal protein antigens, whole cell vaccines, and recombinant bacteria carrying pneumococcal antigens. The book will be a mix of original research, review articles and commentaries that are focused on the effectiveness of current vaccine and the development of future pneumococcal vaccines.
Dr. Stanley S. Tai
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- streptococcus pneumoniae
- pneumococcal vaccine
- pneumococcal conjugate vaccine
- pneumococcoal invasive disease
- pneumococcal protein antigen
- prevnar 7
- prevnar 13
- streptococcus pneumoniae serotype distribution
- streptococcus pneumoniae antibiotic susceptibility
Last update: 4 February 2013